XW043H7

Potential MS-DRG Relationships (FY2026)

The MS-DRG grouper treats this as a non-operating-room procedure. It appears in the surgical logic of 1 MS-DRG:

• MDC PRE — Chimeric Antigen Receptor (CAR) T-Cell and Other Immunotherapies: DRG 018

From the CMS MS-DRG Definitions Manual, Appendix E. Actual DRG assignment depends on the complete claim.

Related Codes

Same operation — other Body Part

Same table and root operation, differing only in the body part character.

XW033H7 — Introduction of Axicabtagene Ciloleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7

Same operation — other Device / Substance / Technology

Same table and root operation, differing only in the device / substance / technology character.

XW043A7 — Introduction of Ciltacabtagene Autoleucel into Central Vein, Percutaneous Approach, New Technology Group 7, XW043B7 — Introduction of Amivantamab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 7, XW043C7 — Introduction of Autologous Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7, XW043G7 — Introduction of Allogeneic Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7, XW043J7 — Introduction of Tisagenlecleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7, XW043K7 — Introduction of Idecabtagene Vicleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7, XW043L7 — Introduction of Lifileucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7, XW043M7 — Introduction of Brexucabtagene Autoleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7, +5 more

Same operation — other Qualifier

Same table and root operation, differing only in the qualifier character.

XW043H5 — Introduction of Tocilizumab into Central Vein, Percutaneous Approach, New Technology Group 5, XW043H6 — Introduction of Other New Technology Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6

Contextual Map

Every relationship of XW043H7 in one view: hierarchy, official tabular instructions in both directions, clinical classification, risk adjustment, MS-DRG participation, index terms and change history — each edge carrying the CMS source it derives from.

PCS table

• XW0[PCS table]
• [object Object] — Section: [object Object] [Section]: “[object Object]”
• [object Object] — Body System: [object Object] [Body System]: “[object Object]”
• [object Object] — Operation: [object Object] [Operation]: “[object Object]”

MS-DRG participation

• DRG 018 — CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL AND OTHER IMMUNOTHERAPIES [MS-DRG]: “CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL AND OTHER IMMUNOTHERAPIES — Chimeric Antigen Receptor (CAR) T-Cell and Other Immunotherapies (MDC PRE)”

MDC crossing · diagnoses (1333)

• Pre-MDC[MDC crossing]: “Pre-MDC — the grouper's crossing between diagnoses and procedures: a principal diagnosis sets the MDC, and same-MDC procedures move the stay to its surgical DRGs.”
• A36.0 — Pharyngeal diphtheria [Same-MDC diagnosis]: “Pharyngeal diphtheria — grouped in MDC PRE, the diagnosis side of this code's crossing.” · check together
• A36.1 — Nasopharyngeal diphtheria [Same-MDC diagnosis]: “Nasopharyngeal diphtheria — grouped in MDC PRE, the diagnosis side of this code's crossing.” · check together
• A36.2 — Laryngeal diphtheria [Same-MDC diagnosis]: “Laryngeal diphtheria — grouped in MDC PRE, the diagnosis side of this code's crossing.” · check together
• A54.5 — Gonococcal pharyngitis [Same-MDC diagnosis]: “Gonococcal pharyngitis — grouped in MDC PRE, the diagnosis side of this code's crossing.” · check together
• A56.4 — Chlamydial infection of pharynx [Same-MDC diagnosis]: “Chlamydial infection of pharynx — grouped in MDC PRE, the diagnosis side of this code's crossing.” · check together
• and 1328 more

Nearest codes

• XW033H7 — Introduction of Axicabtagene Ciloleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7 [One axis away]
• XW04357 — Introduction of Narsoplimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 7 [One axis away]
• XW04367 — Introduction of Terlipressin into Central Vein, Percutaneous Approach, New Technology Group 7 [One axis away]
• XW04377 — Introduction of Trilaciclib into Central Vein, Percutaneous Approach, New Technology Group 7 [One axis away]
• XW04387 — Introduction of Lurbinectedin into Central Vein, Percutaneous Approach, New Technology Group 7 [One axis away]
• XW043A7 — Introduction of Ciltacabtagene Autoleucel into Central Vein, Percutaneous Approach, New Technology Group 7 [One axis away]
• XW043B7 — Introduction of Amivantamab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 7 [One axis away]
• XW043C7 — Introduction of Autologous Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7 [One axis away]